- Home
- MYGN vs FRME Comparison
MYGN vs FRME Comparison
Compare MYGN & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- FRME
- Stock Information
- Founded
- MYGN 1991
- FRME 1893
- Country
- MYGN United States
- FRME United States
- Employees
- MYGN N/A
- FRME N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FRME Major Banks
- Sector
- MYGN Health Care
- FRME Finance
- Exchange
- MYGN Nasdaq
- FRME Nasdaq
- Market Cap
- MYGN 2.0B
- FRME 2.1B
- IPO Year
- MYGN 1995
- FRME N/A
- Fundamental
- Price
- MYGN $15.25
- FRME $43.48
- Analyst Decision
- MYGN Buy
- FRME Buy
- Analyst Count
- MYGN 12
- FRME 5
- Target Price
- MYGN $27.64
- FRME $43.90
- AVG Volume (30 Days)
- MYGN 990.7K
- FRME 378.2K
- Earning Date
- MYGN 11-07-2024
- FRME 10-24-2024
- Dividend Yield
- MYGN N/A
- FRME 3.22%
- EPS Growth
- MYGN N/A
- FRME N/A
- EPS
- MYGN N/A
- FRME 3.01
- Revenue
- MYGN $823,600,000.00
- FRME $593,089,000.00
- Revenue This Year
- MYGN $13.85
- FRME N/A
- Revenue Next Year
- MYGN $7.73
- FRME $2.26
- P/E Ratio
- MYGN N/A
- FRME $14.45
- Revenue Growth
- MYGN 12.15
- FRME N/A
- 52 Week Low
- MYGN $15.18
- FRME $30.20
- 52 Week High
- MYGN $29.30
- FRME $45.08
- Technical
- Relative Strength Index (RSI)
- MYGN 16.18
- FRME 67.52
- Support Level
- MYGN $16.86
- FRME $36.18
- Resistance Level
- MYGN $19.60
- FRME $45.08
- Average True Range (ATR)
- MYGN 1.17
- FRME 1.28
- MACD
- MYGN -0.25
- FRME 0.50
- Stochastic Oscillator
- MYGN 0.90
- FRME 82.02
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.